Aethlon Medical (DB:EJU0) - Aandelenkoers, Nieuws & Analyse

EJU0 Overzicht aandelen

EJU0 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Risicoanalyse

Heeft minder dan 1 jaar cash runway

Heeft geen betekenisvolle marktkapitalisatie ( €6M )

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

De winst zal naar verwachting de komende drie jaar met gemiddeld 4.5% per jaar dalen.

+ 3 meer risico's

Aethlon Medical, Inc. Concurrenten

Audientes

DB:AUG

€6.9m

Geratherm Medical

XTRA:GME

€23.6m

aap Implantate

XTRA:AAQ1

€22.4m

NanoRepro

XTRA:NN6

€19.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Aethlon Medical
Historische aandelenkoersen
Huidige aandelenkoers	US$0.34
52 Week Hoogtepunt	US$1.95
52 Week Laag	US$0.20
Bèta	1.75
11 maand verandering	1.82%
3 maanden verandering	-9.19%
1 Jaar Verandering	-78.04%
33 jaar verandering	-98.38%
5 jaar verandering	n/a
Verandering sinds IPO	-98.10%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	EJU0	DE Medical Equipment	DE Markt
7D	2.4%	2.8%	1.1%
1Y	-78.0%	-5.7%	7.2%

Rendement versus industrie: EJU0 presteerde slechter dan de German Medical Equipment -sector, die het afgelopen jaar een rendement van -5.7 % opleverde.

Rendement versus markt: EJU0 presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 7.2 % opleverde.

Prijsvolatiliteit

Is EJU0's price volatile compared to industry and market?
EJU0 volatility
EJU0 Average Weekly Movement	17.8%
Medical Equipment Industry Average Movement	6.2%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van EJU0 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 18% ) van EJU0 is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen German.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1984	14	Jim Frakes	www.aethlonmedical.com

Aethlon Medical, Inc. is een medisch-therapeutisch bedrijf dat zich richt op de ontwikkeling van producten voor de behandeling van kanker en levensbedreigende infectieziekten in de Verenigde Staten. Het ontwikkelt Hemopurifier, een immunotherapeutisch apparaat in klinische fase voor kanker en levensbedreigende virale infecties en gebruik bij orgaantransplantatie. Het bedrijf werd opgericht in 1984 en is gevestigd in San Diego, Californië.

Aethlon Medical, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Aethlon Medical zich tot de beurswaarde?
EJU0 fundamentele statistieken
Marktkapitalisatie	€5.22m
Inkomsten(TTM)	-€10.67m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.5x

Koers/Winstverhouding

Is EJU0 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
EJU0 resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$11.27m
Inkomsten	-US$11.27m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.81
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde EJU0 op de lange termijn?

Bekijk historische prestaties en vergelijking

EJU0 Overzicht aandelen

Risicoanalyse

Aethlon Medical, Inc. Concurrenten

DB:AUG

€6.9m

XTRA:GME

€23.6m

XTRA:AAQ1

€22.4m

XTRA:NN6

€19.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

New major risk - Revenue and earnings growth

Aethlon Medical Announces Enrollment of the First Patient in (FPI) Its Hemopurifier Cancer Trial in Australia

Aethlon Medical, Inc. to Report Q2, 2025 Results on Nov 13, 2024

Aethlon Medical, Inc. Receives Ethics Committee Approval for Hemopurifier Cancer Trial in India

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier Cancer Trial

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier Cancer Trial

Recent updates

New major risk - Revenue and earnings growth

Aethlon Medical Announces Enrollment of the First Patient in (FPI) Its Hemopurifier Cancer Trial in Australia

Aethlon Medical, Inc. to Report Q2, 2025 Results on Nov 13, 2024

Aethlon Medical, Inc. Receives Ethics Committee Approval for Hemopurifier Cancer Trial in India

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier Cancer Trial

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier Cancer Trial

Aethlon Medical, Inc. Announces Publication of Preclinical Data Showing Ability of the Hemopurifier to Remove Extracellular Vesicles and MicroRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Donor Kidneys

Aethlon Medical, Inc., Annual General Meeting, Sep 27, 2024

Aethlon Medical, Inc. Receives Second Ethics Committee Approval for Hemopurifier Cancer Trial

Aethlon Medical, Inc. to Report Q1, 2025 Results on Aug 14, 2024

Aethlon Medical, Inc. to Report Fiscal Year 2024 Results on Jun 27, 2024

Aethlon Medical, Inc. Receives Ethics Committee Approval for Hemopurifier® Cancer Trial

Aethlon Medical, Inc. Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies

New major risk - Shareholder dilution

Aethlon Medical, Inc. has completed a Follow-on Equity Offering in the amount of $4.69235 million.

Aethlon Medical, Inc. Reports Positive Results from an In Vitro Binding Study of Its Hemopurifier in Removing Extracellular Vesicles from Cancer Patient Plasma

Aethlon Medical, Inc. has filed a Follow-on Equity Offering in the amount of $16.32 million.

Aethlon Medical, Inc. to Report Q3, 2024 Results on Feb 14, 2024

New major risk - Financial position

Aethlon Medical, Inc. Announces Appointment Ofguy Ciprian as Chief Operating Officer

Aethlon Medical, Inc. to Report Q2, 2024 Results on Nov 14, 2023

Aethlon Medical, Inc. Receives Clearance from Drug Controller General of India for Potential Phase 1 Trial of its Hemopurifier(R) in Oncology

Aethlon Medical, Inc. to Report Q1, 2024 Results on Aug 10, 2023

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2023

Aethlon Medical, Inc. Appoints Nicolas Gikakis as Member of the Board and Member of the Nominating Committee

New major risk - Shareholder dilution

Full year 2023 earnings released: US$0.59 loss per share (vs US$0.71 loss in FY 2022)

Aethlon Medical, Inc. to Report Q4, 2023 Results on Jun 28, 2023

No longer forecast to breakeven

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.16 loss in 3Q 2022)

Aethlon Medical, Inc. to Report Q3, 2023 Results on Feb 13, 2023

Forecast to breakeven in 2023

No longer forecast to breakeven

First half 2023 earnings released: US$0.37 loss per share (vs US$0.29 loss in 1H 2022)

Aethlon Medical, Inc. to Report Q2, 2023 Results on Nov 14, 2022

Aethlon Medical Receives Non-Compliance Notice of Delisting from Nasdaq

Aethlon Medical, Inc. Announces Early Feasibility Study of the Hemopurifier

Forecast to breakeven in 2023

Aethlon Medical, Inc. to Report Q1, 2023 Results on Aug 09, 2022

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2022

Aethlon Medical, Inc. Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment

Aethlon Medical, Inc. to Report Fiscal Year 2022 Results on Jun 28, 2022

Insufficient new directors

Aethlon Medical, Inc. Announces Executive Changes

Aethlon Medical, Inc. to Report Q3, 2022 Results on Feb 14, 2022

Insufficient new directors

Full year 2021 earnings released: US$0.65 loss per share (vs US$1.87 loss in FY 2020)

Aethlon Medical, Inc. Publishes Case Studies of Two Critically ill Covid-19 Patients Treated with the Hemopurifier®

Forecast to breakeven in 2023

Third quarter 2021 earnings released: US$0.20 loss per share (vs US$0.28 loss in 3Q 2020)

Revenue beats expectations

New 90-day high: €2.30

Aethlon Medical, Inc. to Report Q3, 2021 Results on Feb 10, 2021

Aethlon Medical, Inc. Announces Executive Appointments

New 90-day high: €2.10

Aethlon Medical, Inc. Announces First Patient Treated in First-in-Human Clinical Trial of HEMOPURIFIER® in Head and Neck Cancer

New 90-day high: €1.94

New 90-day high: €1.49

Aethlon Medical, Inc. Announces Board Changes, Effective as of October 30, 2020

Aethlon Medical, Inc. Announces Executive Changes, Effective as of October 30, 2020